Researchers are hoping to produce a vaccine ready for clinical trials in mere months, significantly trimming down a process that can take up to a decade.
ADVERTISEMENTLess than two weeks after a new coronavirus was first reported in China, scientists published a dizzying string of more than 34,000 letters: the molecular blueprint of the respiratory illness.
Scientists around the world immediately seized on those letters, the virus's sequenced genome, in an effort to create a vaccine that could help halt the spreading pathogen. Researchers are hoping to produce a vaccine ready for clinical trials in mere months, significantly trimming down a process that, in some cases, can take up to a decade.
"Basically, we've gotten a lot better at doing this," Alex Greninger, a virologist at the University of Washington in Seattle, said of genome sequencing efforts. "The CDC already had a diagnostic test ready by the time the first patient that they tested came in. That's amazing and it's really thanks to the sharing of that initial genome."
The race is on for scientists to develop responses to the new coronavirus pathogen. As of Wednesday, the virus had sickened almost 6,000 people and killed 132. Cases of the virus have been reported in 14 countries outside of China, including five confirmed cases in the U.S.
Scientists and research organizations around the world sprang into action after the first coronavirus case in the Chinese city of Wuhan was reported to the World Health Organization on Dec. 31, 2019. They say efforts to develop vaccines for previous coronavirus outbreaks combined with new technologies are shortening what remains a lengthy and arduous process.
Scientists at the Peter Doherty Institute for Infection and Immunity in Melbourne, Australia, have produced a lab-grown version of the new coronavirus that they say could help speed the development of a vaccine and diagnostic test. And Johnson & Johnson announced Wednesday that it would use the same technologies from their lab's development of an experimental Ebola vaccine to produce vaccine candidates for the new coronavirus.
Work on a vaccine is also underway at the National Institutes of Health. Anthony Fauci, director of the NIH's National Institute of Allergy and Infectious Diseases has said that the first phase of clinical trials could begin within three months. A consortium of scientists in the U.S. and Canada, led by Karla Satchell at Northwestern University, is also sifting through the virus's genetic code for clues about how to stop it from spreading.
On Jan. 23, the Coalition for Epidemic Preparedness Innovations, an organization founded in 2016 to foster the development of new vaccines for emerging infectious diseases, announced that it was funding three separate approaches to develop vaccines against the coronavirus.
The coalition partnered with two biotech companies — the Pennsylvania-based Inovio and Massachusetts-based Moderna Inc. — and the University of Queensland in Australia with the aim of advancing potential vaccines to clinical trials in about four months.
#embed-20200122-coronavirus-world-count iframe {width: 1px;min-width: 100%}
"There are no guarantees of success, but we hope this work could provide a significant and important step forward in developing a vaccine for this disease," Richard Hatchett, CEO of the coalition,said in a statement.
One aspect the coalition is emphasizing is speed. Advances in genetic technologies and widespread cooperation among scientists around the world are enabling labs to analyze the virus in near real-time.
In 2003, an outbreak of Severe Acute Respiratory Syndrome (SARS), a type of coronavirus that closely resembles the Wuhan variant, spread to more than two dozen countries and killed 774 people. At the time, it took scientists in the United States 20 months to advance from sequencing the virus's genome to human trials of potential vaccines.
Hatchett is hoping to cut that process down to 16 weeks by investing in technologies to produce and test vaccines faster, and by applying research conducted on other coronaviruses that are thought to be closely related to the Wuhan pathogen.
Novavax, a biotech company headquartered in Gaithersburg, Maryland, is also banking on the ability to apply lessons learned from previous vaccine development programs. The firm has worked on vaccines for the flu, in addition to pandemic-level outbreaks such as Ebola, SARS and Middle East Respiratory Syndrome, or MERS, another type of coronavirus that was first reported in Saudi Arabia in 2012.
Gregory Glenn, head of research and development at Novavax, said the company's previous work on coronaviruses such as SARS and MERS could help speed up vaccine development.
"We think we can get to a vaccine fairly quickly, so we felt like we had no choice," he said.
For now, Novavax is investing internally in this research, but Glenn said the company would eventually need outside funding to continue through the various testing phases. Still, he thinks Novavax could mass produce millions of doses in a year if one of its experimental vaccines showed success in clinical trials.
ADVERTISEMENTBut millions of doses would be insufficient to protect people in even just one country, particularly as officials are bracing for the virus to continue spreading.
Even the most state-of-the-art vaccine development can be a long and expensive process. If researchers can get an experimental vaccine to clinical trials in four months — a feat in and of itself — it would still likely take at least a year before those vaccines are commercially available.
So while vaccines are an extremely important way to prevent infectious diseases, they are not necessarily the most practical solution during an outbreak, said Michael Osterholm, director of the Center for Infectious Disease Research and Policy at the University of Minnesota.
"Every time we get an outbreak, there's an outpouring of voices saying we're going to have a vaccine," he said. "I wish we had these vaccines, too, but transferring the Grand Canyon to the state of New York is probably more practical at this point."
Osterholm said the approval process for new vaccines is lengthy and it's more often the case that outbreaks have already receded by the time doses are commercially manufactured and available.
ADVERTISEMENTThe SARS vaccines developed by Novavax, for instance, were never mass produced because public health officials were able to contain the virus. The outbreak ended after about six months, and according to the CDC, there have been no known transmissions since July 2003.
And though work on an Ebola vaccine has been in the works for decades, efforts were ramped up after a severe outbreak in West Africa in 2014. Still, the first Ebola vaccine was only recently approved by the U.S. Food and Drug Administration in December.
But Glenn said there is still value in investing in vaccine development early on during outbreaks, especially as technologies improve and scientists are able to be more agile with this type of research.
"We live in a time when there are so many tools available," he said. "It has to be possible that we'll crunch that time down from recognizing a novel virus to having a new vaccine. Even just two years from now, we should have this conversation again and see how we did."